Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    cardiovascular diseaseIn his most recent study, Angelos Halaris, MD, PhD, and colleagues found that an inflammatory biomarker, interleukin-6, was significantly higher in the blood of 48 patients diagnosed with major depression than it was in 20 healthy controls. Interleukin-6 has been associated with cardiovascular disease. Halaris presented findings at a joint congress of the World Psychiatric Association and International Neuropsychiatric Association in Athens, Greece. At the congress, Halaris formally proposed creation of a new Psychocardiology subspecialty.

    Forty to 60 percent of heart disease patients suffer clinical depression and 30 to 50 percent of patients who suffer clinical depression are at risk of developing cardiovascular disease, Halaris said.

    Stress is the key to understanding the association between depression and heart disease. Stress can lead to depression, and depression, in turn, can become stressful.

    The body’s immune system fights stress as it would fight a disease or infection. In response to stress, the immune system produces proteins called cytokines, including interleukin-6. Initially, this inflammatory response protects against stress. But over time, a chronic inflammatory response can lead to arteriosclerosis (hardening of the arteries) and cardiovascular disease.

    It’s a vicious cycle: depression triggers a chronic inflammation, which leads to heart disease, which causes depression, which leads to more heart disease.

    Clinical depression typically begins in young adults. “Treating depression expertly and vigorously in young age can help prevent cardiovascular disease later on,” Halaris said.

    Physicians often work in isolation, with psychiatrists treating depression, and cardiologists treating cardiovascular disease. Halaris is proposing that psychiatrists and cardiologists work together in a multidisciplinary Psychocardiology subspecialty.

    A Psychocardiology subspecialty would raise awareness among physicians and the public. It would forge closer working relationships between psychiatrists and cardiologists. It would formalize multidisciplinary teams with the requisite training and expertise to enable early detection of cardiovascular disease risk in psychiatric patients and psychiatric problems in heart disease patients. And it would provide continuing education to physicians in the safe and correct use of medications in cardiac patients who have psychiatric disorders.

    “It is only through the cohesive interaction of such multidisciplinary teams that we can succeed in unravelling the complex relationships among mental stress, inflammation, immune responses and depression, cardiovascular disease and stroke,” Halaris said.

    Halaris is Medical Director of Adult Psychiatry and a Professor in the Department of Psychiatry and Behavioral Neurosciences at Loyola University Chicago Stritch School of Medicine.

    Check out our new Cardiovascular products

    Published in News

    mouseA drug currently approved to treat mouth ulcers has shown promise in animal studies for being a contender in pharmaceutical weight loss. Amlexanox was found by University of Michigan researchers to produce weight loss in obese mice without any change in diet or exercise habits.

    For the study, mice fed a high calorie diet until they became obese were injected with amlexanox. The animals lost weight, despite consuming the same amount of calories. The researchers also noted a loss in overall body fat, a decrease in fatty liver, and a reversal of obesity-induced type 2 diabetes. Once taken off the amlexanox injections, however, the mice experienced weight gain.

    Amlexanox may work by changing the action of genes that control metabolism versus working as an appetite suppressant.

    When the drug was injected in mice, the drug worked by increasing metabolism, not by suppressing appetite.

    "One of the reasons that diets are so ineffective in producing weight loss for some people is that their bodies adjust to the reduced calories by also reducing their metabolism, so that they are 'defending' their body weight," says Dr. Alan Saltiel, the lead researcher at the University of Michigan.

     "Amlexanox seems to tweak the metabolic response to excessive calorie storage in mice."

    The findings were published Sunday in the journal Nature Medicine. Clinical trials are expected to begin later this year to test the drug's effectiveness in humans.

    Published in News
    Friday, 15 February 2013 17:15

    Heat Block Incubator

    wcs-2610-heat-block-incubatorWSC-2610 MyMiniBLOCK

    Do you need only heating function with block incubator? WSC-2610 MyMiniBLOCK is a microprocessor-controlled product using advanced thermoelectric technology. With this technique, more stable and accurate up to 100 C temperature control is achieved. In compact body, very various use such as sample preparation of electrophoresis, DNA/RNA denature and reaction, trans-information of E. coli, etc. can be applied.

     

    WSC-2620 PowerBLOCK

    WSC-2620 PowerBLOCK is able to reach set-temperature in mins.
    It can reach to the target temperature in about 7min, you can easily use it with different temperature just after using with previously set temperature. Wide and stably accurate temperature setting is from –10 to 100o C. It can be used for very wide applications and used in different temperature settings continuously.

     

    WSC-2630 PowerBLOCK Shaker

    WSC-2630 PowerBLOCK Sharker is all-in-one high specification shaking incu- bator. It is available to mix samples while incubating, and setting temperature is from 0 to 100o C. No need cooled or thermostatic room or additional chambers. While using it as conventional block incubator, it is also compatible for more specific application such as Immunoprecipitation assay, ELISA, Bid purification of DNA/RNA that requires mixing while reaction.
     
    Published in Promos
    Thursday, 14 February 2013 10:22

    JX-594 Anti-Cancer Virus Found in Canada

    antibodies-jx-594 cancer-cellsRecent news suggests that Canadian Cancer Specialists have found what researchers have labelled a medical first, in that an engineered virus which is injected into the cancer patients blood stream targets cancer cells throughout the body killing them, or at least not letting them get any bigger. Out of 23 patients, who have highly metabolized cancer, which means that the cancer has spread throughout their body and doesn’t show signs of being decreased, have been injected with a cancer fighting virus which hopes to kill the cancer cells. This is not the first time that a cancer virus has been suggested to the public. However, normally with cancer viruses, the virus itself had to be administered and injected directly into the tumor. This is extremely difficult as, tumors are not always stationary within the human body. The anti-cancer virus JX-594 was injected into the blood of 23 patients. 8 out of the 23 patients had the JX-594 replicating itself inside the cancer tumors, and not spreading into other healthy non-cancer cells.

    "We are very excited because this is the first time in medical history that a viral therapy has been shown to consistently and selectively replicate in cancer tissue after intravenous infusion in humans.” Said, Professor John Bell, who is the lead research from the University of Ottawa. Professor Nick Lemoine, director of Barts Cancer Institute said, “Viruses that multiply in just tumor cells - avoiding healthy cells - are showing real promise as a new biological approach to target hard-to-treat cancers. This new study is important because it shows that a virus previously used safely to vaccinate against smallpox in millions of people can now be modified to reach cancers through the bloodstream - even after cancer has spread widely through the patient's body. "It is particularly encouraging that responses were seen even in tumors like mesothelioma, a cancer which can be particularly hard to treat."

    What happened to the other 15 patients who did not show sign of progress? Well...it’s not said. However, 6 of the patients did have infection which prevented the growth of any tumor progress. JX-594 was only given to the 23 patients at a small does, and only one does, because it is so early in the stages.
     

    Dose-Finding Results

    Oncolytic immunotherapies are designed to selectively replicate within cancer cells and, subsequently, to lyse them, Dr. Reid and colleagues explain. JX-594 is designed to induce virus-replication-dependent oncolysis and tumor-specific immunity, and to disrupt the "viral thymidine kinase gene for cancer selectivity and insertion of human granulocyte-macrophage colony-stimulating factor (hGM-CSF) and beta-galactosidase transgenes for immune stimulation and replication assessment, respectively," they note.

    The complete response of bulky tumors and systemic efficacy was seen in phase 1 trials of JX-594.

    In this phase 2 trial, 30 patients with advanced HCC received 1 of 2 injections into liver tumors on days 1, 15, and 29: low-dose JX-594 (108 pfu) or high-dose JX-594 (109 pfu).

    Kaplan–Meier survival estimates were significantly longer in the high-dose group than in the low-dose group at 1 year (66% vs 23%) and at 18 months (35% vs 11%). Survival did not correlate with the origin of the tumor.

    In the 19 patients with multiple tumors at baseline (10 in the high-dose group and 9 in the low-dose group), median overall survival was longer in the high-dose group (13.6 vs 4.3 months; HR, 0.19; P = .018).

    Median survival in patients with multiple tumors was half that of patients with single tumors (8.8 vs 16.6 months). The authors note that there was no correlation between survival duration and the presence of detectable neutralizing antibodies to the vaccinia virus at baseline, compared with the absence of such antibodies (HR, 0.68)

    Both doses of JX-594 were generally well tolerated, Dr. Reid and colleagues report, and there were no treatment-related deaths. One patient in the high-dose group experienced a treatment-related serious adverse event (nausea and vomiting requiring prolonged hospitalization), and 8 patients (4 in each group) experienced nontreatment-related serious adverse events.

    Antiangiogenesis Results

    In the phase 2 antiangiogenesis trial, Dr. Breitbach and colleagues tested the hypothesis that a vaccinia virus engineered to target cells that activate the ras/MAPK signaling pathway would specifically infect and express transgenes (hGM-CSF, beta-galactosidase) in tumor-associated vascular endothelial cells in humans.

    Preclinical research in mice demonstrated that an intravenous infusion of JX-594 resulted in virus replication in tumor-associated endothelial cells, disruption of tumor blood flow, and hypoxia within 48 hours, and massive tumor necrosis within 5 days. In a phase 1 clinical trial, an intravenous infusion of JX-594 showed dose-dependent endothelial cell infection in tumors.

     

    Dr. Breitbach and colleagues found that JX-594 disrupted perfusion to the tumor as soon as 5 days after treatment in both VEGF-receptor inhibitor-naïve and -refractory patients with advanced HCC.

    This "technology opens up the possibility of multifunctional engineered vaccinia products that selectively target and infect tumor-associated endothelial cells, as well as cancer cells, resulting in transgene expression, vasculature disruption, and tumor destruction in humans systemically," they note.

    Funding for the dose-finding study was provided by Jennerex, Transgene SA, and the Green Cross Corporation. Several coauthors report receiving individual grants, as detailed in the paper.

    Published in News
    Sunday, 10 February 2013 17:44

    Two Antibodies Are Better Than One

    A new approach mimicking the body’s natural defenses could help treat a therapy-resistant breast cancer

    Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner:  They block characteristic molecules on tumor cells – receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

    Some of these therapy-resistant cancers have a potential molecular target for cancer drugs, a growth-factor receptor called EGFR, but an EGFR-blocking drug has proved ineffective in treating them. In a study published recently in the Proceedings of the National Academy of Sciences, Weizmann Institute researchers propose a potential solution: to simultaneously treat triple-negative breast cancer with two EGFR-blocking antibodies instead of one. In a study in mice, the scientists showed that a certain combination of two antibodies indeed prevented the growth and spread of triple-negative tumors. The research team, led by Prof. Yosef Yarden of the Biological Regulation Department and Prof. Michael Sela of the Immunology Department, included Drs. Daniela Ferraro, Nadège Gaborit, Ruth Maron,  Hadas Cohen-Dvashi,  Ziv Porat and Fresia Pareja, and Sara Lavi, Dr. Moshit Lindzen and Nir Ben-Chetrit.

    Of the different combinations they tried, the scientists found that the approach worked when the two antibodies bound to different parts of the EGFR molecule. The combined action of the antibodies was stronger than would have been expected by simply adding up the separate effects of each.  Apparently, the use of the two antibodies created an entirely new anti-cancer mechanism: In addition to blocking the EGFR and recruiting the help of immune cells, the antibodies probably overwhelmed the EGFR by their sheer weight, causing it to collapse inward from the membrane into the tumor cell.
     
    Deprived of EGFR on its surface, the cells were no longer receiving the growth signals, preventing the growth of the tumor. This approach resembles the natural functioning of the immune system, which tends to block essential antigens at several sites by targeting them with multiple antibodies.

    If supported by further studies, the two-antibody approach, in combination with chemotherapy, might in the future be developed into an effective treatment for triple-negative breast cancer.
    Prof. Michael Sela is the incumbent of the W. Garfield Weston Professorial Chair of Immunology.
    Prof. Yosef Yarden’s research is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; the M.D. Moross Institute for Cancer Research; the Steven and Beverly Rubenstein Charitable Foundation , Inc.; Julie Charbonneau, Canada; the European Research Council; and the Marvin Tanner Laboratory for Research on Cancer. Prof. Yarden is the incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology.
     
     
    Published in News
    Friday, 08 February 2013 12:32

    Kronos Dio

    A luminometer for real-time reporter assay with 8 dish incubator and multicolor measurement system

    Kronos dio AB-2550-kronosDioA luminescence monitoring tool to observe gene expressions with bioluminescent markers under long-term culture. Can be used in studies of internal biological clock, circadian rhythms in organisms, gene silencing, drug stimulation, etc. Kronos Dio is equiped with cell culture system within its housing to provide real-time periodical luminescence measurement with multi-color luciferase assay, enabling users to analyse the effects of complex factors influencing gene expression in the cell or the tissue. Internal temperature control (range: 20 to 45 °C) and carbon dioxide circulation allows for convenient cell culture over a long period of time.

     

    Price: 29 500 Euro / 36 000 USD / 27 600 GBP

     

    kronos-dio-gentaur-colours 

    Installation and training

    For the price GENTAUR provides notebook, installation and training (demonstration of basic software and hardware functionality). 6 hours of installation and training is inclusive in the price at no extra cost for USA and Europe. The necessary materials and tools for connecting the device to the Carbone dioxide source at the expense of the customer.

    20141105 033403

    kronos dio installation

    kronos dio installationkronos dio installation kronos dio installation

     

     

     

     

    Download Catalogue

     

    See also: Cellgraph AB-3000B

    Literature

    Customer references:

    Aaron Rowland, Ph.D.
    Assistant Professor of Toxicology
    Department of Chemistry & Biochemistry
    New Mexico State University
    1175 North Horseshoe Drive
    P.O. Box 30001
    Las Cruces, NM 88003-8001


    We are wanting to explore the ability of human breast cell lines to exhibit circadian rhythm.  We are also interested in influence of environmental toxicants on circadian rhythm as well as general gene regulation.  I felt that the Kronos dio would be the proper equipment to perform this task as it has a CO2 hook up and can monitor 3 colors at once.  Therefore, I could transfect the BASIC luciferase construct using one color and the gene of interest using a different luciferase and monitor reporter activity in real time.  
    Observation that Irritant of Environmental toxin on Human’s breast cell lines reaction and changes.

     

    Order Button1 

    Published in Promos

    The quest for longer and healthier life, if not immortality, has been part of the human experience since we evolved the ability to recognize the total annihilation of individual death. Our understanding of the biology of aging at the molecular level is advancing so rapidly that it appears inevitable that another decade or two of life will be enabled before long. A new step in what may be the right direction has just been published by researchers at the University of California, Berkeley.

    The ravages of aging appear to be related to oxidative stress combined with telomere exhaustion, along with many other known and unknown factors. The subject of the new Berkeley study is a class of proteins called sirtuins that are known to play a central role in regulating aging and longevity in many non-human models (such as mice).

    There is good evidence that these proteins also play a similar role in humans. For example, research has shown that, of two variants of the SIRT3 sirtuin protein (known to have strong anti-oxidant properties), humans who live past 90 years of age only have one of the variants in their bodies, the variant that enhances production of SIRT3. The difference between the two variants results from a change of one gene by one mutation, and appears to be sufficient to significantly affect an organism's longevity. This suggests a strong link between SIRT3 and longevity.

    The genetics of longevity are quite interesting, but still more interesting would be finding an approach to offset the hand you were dealt at birth, or better yet, to stack the deck. The authors of the Berkeley study decided to see if SIRT3 could rejuvenate blood stem cells extracted from old mice.

    Their first step was to see what happened as mice, which did not possess the SIRT3 gene, aged. When young, these "knockout" mice followed the same course of aging as did a set of normal control mice. However, when the mice were two years old (about an average lifespan for a lab mouse), the knockout mice had far fewer blood stem cells than did the control group.

    What causes the difference in the course of aging? Young cells have low levels of oxidative stress (the generation of reactive oxygen species during metabolism), low enough that the body's normal anti-oxidants can keep up with the resulting damage. When they get older, they can't keep up, and need a boost of SIRT3 to help them. When there is no SIRT3, the progress of old age occurs sooner and more rapidly.

    “When we get older, our system doesn’t work as well, and we either generate more oxidative stress or we can’t remove it as well, so levels build up,” said Chen. “Under this condition, our normal anti-oxidative system can’t take care of us, so that’s when we need SIRT3 to kick in to boost the anti-oxidant system. However, SIRT3 levels also drop with age, so over time, the system is overwhelmed.”

    So it appears that age-related degeneration speeds up in the absence of SIRT3 in the system – at least among mice. The Berkeley team decided to see if increasing SIRT3 levels could rehabilitate the blood stem cells. This was done by infusing the blood stem cells with the SIRT3 protein, following which their ability to make new blood cells did indeed return.

    Further studies will address if SIRT3-induced rejuvenation will apply to whole organisms, so that they might live longer when so treated, even after experiencing normal aging events.

    Published in News
    Tuesday, 05 February 2013 11:34

    BULLET BLENDER

    bullet-blender-blue-by-gentaur

    bullet-blender-blue-by-gentaur-hood-openThe BULLET BLENDER® enables you to homogenize, disrupt, or lyse up to 24 tissue or cell culture samples at a time. Load the samples into standard polypropylene tubes, then place them in the BULLET BLENDER. The "bullets" in the instrument vigorously strike all of the tubes and homogenize your sample in minutes. The Bullet Blender is available with Air Cooling™ to preserve your sample quality!

     

    Applications:

     

    Homogenize Tissue
    Liver, Spleen, Kidney, Brain, Adipose, Bladder, Eye, Thyroid, Gallbladder, Muscle, Pancreas, Testes, Meconium, Thymus

    Homogenize Tougher Tissue
    Heart, Aorta, Tumor, Tail Snips, Colon, Lung, Blood Vessel, Trachea, Cartilage, Epithelium, Stomach, Intestine, Larynx, Mouse Femur, Pharynx, Umbilical Cord, Skin, Uterus

    Lyse Cells
    E. coli, Mamallian cell culture, Yeast

    Homogenize Plant Material
    Leaves, Beans, Nuts, Roots

    Homogenize Small Organisms
    Zebrafish, Drosophila

    Whole Cell Isolation
    Bacteria, Lymphocytes, Blood Cells

    Organelle Isolation
    Nucleus, Mitochondria

    Click here for more information

    More form Gentaur: Order Beads for Bullet Blender

     Order Button1

    Published in Promos

    Millions of lives have been changed over the past fourthy years because of advances in medical technology. From stem-cell research to reengineering the way we take our daily medications, all these developments have brought health care into the 21st century. There has been a vast disconnect between these improvements and the manufacturing processes used to provide influenza vaccines to the public.

    Shockingly, the method used to produce the influenza vaccine has not been significantly transformed since 1931, when vaccines used for preventive care were first introduced to the public.

    Influenza causes between 3,000 and 48,000 deaths and 190,000 hospitalizations in any given season, so it is critical to utilize the most effective production methods to create influenza vaccines to protect our communities. Until recently, all influenza vaccines available in the U.S. were produced by growing and harvesting the virus in chicken eggs. During the time this method has been successful, millions of eggs are needed to produce enough vaccine for our communities each year, requiring production to begin many months in advance. Once the virus strains are selected for the upcoming influenza season by the WHO (World Health Organization), and companies begin manufacturing the vaccine, it can take anywhere between 6 and 9 months to make the vaccine available to physicians or pharmacists.

    The egg-based manufacturing process has been working for us to date; however, there is a new process that raises the bar in influenza vaccine manufacturing, is less time-consuming and brings the manufacturing process into the digital age.

    Cell-culture technology is the latest production technique for influenza vaccine manufacturing, which involves growing the virus in cells from mammals, rather than chicken eggs. This method offers advantages over the conventional egg-based process:

    • Since no eggs need to be collected, vaccines can be produced and available to the public quicker, which is critical in case of a flu pandemic.

    • The process does not use any preservatives or antibiotics during production.

    Cell-culture technology has been successfully used to manufacture many other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. This technology also has been tried and tested in other countries, which have already approved and use cell-based influenza vaccines abroad. Recently, the FDA gave its stamp of approval to use the technology in influenza vaccines available in the U.S., with an approval of a cell-based seasonal influenza vaccine.

    It is important that such a fundamental vaccine that every American ages 6 months and older is advised to receive each year is available using the most cutting-edge technology. I am excited to see how this major advancement will help start a new chapter in the evolution of influenza prevention.

    Published in News

    Further research conducted for the annual 2013 Cell Line Development & Engineering conference in Vienna next February, showed major developments in cell culture systems have given biotech's and pharmaceutical companies more flexibility to scale up cells to a high manufacturing quality.The production of high-performing cell lines have been enabled by cell engineering tools and this has only been possible through improvements in cell culture media.

    For best accommodation of these new developments, Informa Life Sciences' have expanded the programme to cover the latest in cell line development strategies and improvements in cell culture systems. Alison Porter, Head of Cell Line Development in the Mammalian Cell Culture group at Fujifilm Diosynth Biotechnologies (FFDB) clarifies how "For first in human studies with cell line construction on the critical path, it is vital to have optimised the early stages of cell line development. This can improve the future success of a biotherapeutic, both in terms of having the 'best' cell line and meeting increasingly tight timelines."

    Further feedback from over 50 industry professionals and academics also highlight additional trends such as high throughput screening of cell lines, Quality by Design applications, cell line development strategies for novel products, analytical tools for product evaluation and bioinformatics applications.

    Informa's annual 2013 Cell Line Development & Engineering conference has been designed to address topics essential to improve product development and quality. Susanna Benaim Conference Producer at Informa Life Sciences explains "The event uncovers the essentials in micro-scale system application, CHO genome sequencing, cell line engineering and targeted integration. The conference brings together leading experts from protein engineering, cell biology, cell line development and bioprocess, from both the pharmaceutical industry and academia. Any company specialising in this area is encouraged not to miss out."

    Published in News
    Page 3 of 3